JOP20240188A1 - معالجة سرطان تستهدف dll3 - Google Patents

معالجة سرطان تستهدف dll3

Info

Publication number
JOP20240188A1
JOP20240188A1 JOJO/P/2024/0188A JOP20240188A JOP20240188A1 JO P20240188 A1 JOP20240188 A1 JO P20240188A1 JO P20240188 A JOP20240188 A JO P20240188A JO P20240188 A1 JOP20240188 A1 JO P20240188A1
Authority
JO
Jordan
Prior art keywords
dll3
cancer treatment
treatment targeting
targeting dll3
agent
Prior art date
Application number
JOJO/P/2024/0188A
Other languages
Arabic (ar)
English (en)
Inventor
Xi Chen
Amanda Goldrick
Mira Kistler
Mukul Minocha
Sadraei Nooshin Hashemi
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of JOP20240188A1 publication Critical patent/JOP20240188A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JOJO/P/2024/0188A 2022-02-23 2024-08-19 معالجة سرطان تستهدف dll3 JOP20240188A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263313119P 2022-02-23 2022-02-23
US202263429311P 2022-12-01 2022-12-01
PCT/US2023/063010 WO2023164474A1 (en) 2022-02-23 2023-02-22 Cancer treatment targeting dll3

Publications (1)

Publication Number Publication Date
JOP20240188A1 true JOP20240188A1 (ar) 2024-08-19

Family

ID=85724660

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2024/0188A JOP20240188A1 (ar) 2022-02-23 2024-08-19 معالجة سرطان تستهدف dll3

Country Status (12)

Country Link
US (1) US20250154247A1 (https=)
EP (1) EP4482586A1 (https=)
JP (1) JP2025508786A (https=)
KR (1) KR20240153575A (https=)
AU (1) AU2023224210A1 (https=)
CA (1) CA3252459A1 (https=)
CL (1) CL2024002529A1 (https=)
IL (1) IL314195A (https=)
JO (1) JOP20240188A1 (https=)
MX (1) MX2024010330A (https=)
TW (1) TW202342096A (https=)
WO (1) WO2023164474A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025080688A1 (en) * 2023-10-12 2025-04-17 Amgen Inc. Compositions of bispecific antibody constructs to human dll3 and human cd3
TW202602488A (zh) * 2024-03-11 2026-01-16 美商安進公司 治療ｄｌｌ３陽性癌症受試者中腦轉移之方法
WO2026008059A1 (en) * 2024-07-04 2026-01-08 Nanjing Legend Biotech Co., Ltd. Anti-dll3 constructs and uses thereof
WO2026075950A1 (en) * 2024-10-01 2026-04-09 Amgen Inc. Dosing regimen for anti-dll3 agent

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112324B1 (en) 1998-04-21 2006-09-26 Micromet Ag CD 19×CD3 specific polypeptides and uses thereof
MXPA06004035A (es) 2003-10-16 2006-08-31 Micromet Ag Aglutinantes cd3 de-inmunizados multi-especificos.
RS53008B2 (sr) 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
MX2018002166A (es) * 2015-08-20 2018-09-12 Abbvie Stemcentrx Llc Conjugados anticuerpo anti-dll3-farmaco y metodos de uso.
JP7314146B2 (ja) 2017-12-28 2023-07-25 中外製薬株式会社 細胞傷害誘導治療剤
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
EP3819312A1 (en) * 2019-11-10 2021-05-12 Amgen, Inc Dosing regimen for anti-dll3 agents
US11976133B2 (en) 2020-01-31 2024-05-07 Gensun Biopharma Inc. Bispecific T cell engagers
CR20220541A (es) 2020-03-31 2022-11-28 Chugai Pharmaceutical Co Ltd Moléculas de unión al antígeno multiespecíficas dirigidas a ligando de tipo delta 3 (dll3) y sus usos
IL307646A (en) * 2021-05-10 2023-12-01 Amgen Inc Dosing regimen for combination therapy targeting DLL3 and PD-1

Also Published As

Publication number Publication date
IL314195A (en) 2024-09-01
US20250154247A1 (en) 2025-05-15
CA3252459A1 (en) 2023-08-31
CL2024002529A1 (es) 2025-01-24
EP4482586A1 (en) 2025-01-01
TW202342096A (zh) 2023-11-01
KR20240153575A (ko) 2024-10-23
WO2023164474A1 (en) 2023-08-31
MX2024010330A (es) 2024-08-30
AU2023224210A1 (en) 2024-07-18
JP2025508786A (ja) 2025-04-10

Similar Documents

Publication Publication Date Title
JOP20240188A1 (ar) معالجة سرطان تستهدف dll3
MX2023013227A (es) Regimen de dosis para terapia combinada dirigida a dll3 y pd-1.
PH12021550407A1 (en) Anti-pd-1/vegfa bifunctional antibody, pharmaceutical composition thereof and use thereof
GEAP202516662A (en) Anti-nectin-4 antibody, conjugate including same, and application thereof
CO2019013020A2 (es) Anticuerpo anti-cdh6 y conjugado farmaco-anticuerpo anticdh6
BR112022026236A2 (pt) Terapia de combinação de imuno-oncologia com conjugados de il-2 e anticorpos anti-egfr
JOP20220104A1 (ar) نظام تجريع لعوامل مضادة لـ dll3
Kudo et al. Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha‐fetoprotein after sorafenib in REACH and REACH‐2
CO2023009635A2 (es) Conjugado de anticuerpo anti-dll3-fármaco
EA202190403A1 (ru) Лечение метастатической опухоли головного мозга путем введения конъюгата антитело-лекарственное средство
CO2021016606A2 (es) Métodos para administrar un anticuerpo anti-cd38 para tratar el mieloma múltiple
MX386434B (es) Métodos para aumentar en plasma sanguíneo la 2'-desoxiuridina (durd) y la inhibición de la timidilato sintasa.
BR112022009482A2 (pt) Anticorpo monoclonal anti-b7-h3 e métodos de uso do mesmo
JOP20230243A1 (ar) طرق لعلاج السرطان بواسطة إعطاء أجسام مضادة موجّهة ضد pd1 تحت الجلد
JOP20230112A1 (ar) أجسام مضادة لـ cd48، متقارنات الجسم المضاد مع العقار، واستخداماتها
EP4424709A3 (en) Dosing regimen for anti-bcma agents
MX2022003610A (es) Administracion de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
CL2025002930A1 (es) Programa de dosificación de un inhibidor de her.2
MX2024007749A (es) Formulaciones clinicas de anticuerpos anti-tigit.
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
MX2023013614A (es) Uso de conjugado farmaco-anticuerpo en combinacion con inhibidor de puntos de control inmunitario en el tratamiento del cancer urotelial.
JOP20250015A1 (ar) تركيبة صيدلانية للأجسام المضادة ضد cd20 واستخداماتها
Subramanium et al. Nimotuzumab with induction chemotherapy and chemo-radiation in patients with advanced head and neck cancer
MX2023006404A (es) Terapia combinada de anticuerpos y taxanos.
MX2019010086A (es) Esquema de dosificacion para una combinacion de ceritinib y una molecula de anticuerpo anti-pd-1.